SCOTUS to review Amgen-Sanofi patent battle as a proxy for how narrowly pharma patents will need to be written

The Supreme Court has agreed to take up a long-running patent battle between PCSK9 frontrunners Amgen and Sanofi that has spilled into a broader issue of how narrowly pharma patents should be written.

The decision means the highest court in the US agrees to address what’s referred to as the...

Click to view original post